ClariTrial | Search Clinical Trials

Explore/autoimmune immunology

Status

Phase

Pre-filtered to show active, later-stage trials with the strongest clinical signal.

41 results for “autoimmune immunology” · Recruiting · Phase 3 · Phase 2

Page 1 of 3

Recruiting

A Study of Nipocalimab in Adults With Moderate to Severe Systemic Lupus Erythematosus

Phase 3Lupus Erythematosus, Systemic

NipocalimabPlaceboStandard of care treatment

Janssen Research & Development, LLC600 participants260 sites · United States, Argentina, AustraliaCompletes Dec 2028

Compare CT.gov Full analysis →

Recruiting

Belimumab in Autoimmune Hepatitis

Phase 2Autoimmune Hepatitis

Belimumab Auto-Injector [Benlysta]

University Health Network, Toronto48 participants5 sites · CanadaCompletes Apr 2028

Compare CT.gov Full analysis →

Recruiting

Exploratory Study of Anti-BCMA-CD19 CAR-T Cell Therapy in Relapsed or Refractory IgG4-Related Disease

Phase 2IgG4 Related DiseaseB-cell Mediated Autoimmune Disorders

Anti-BCMA-CD19 CAR-T cells

Chinese PLA General Hospital9 participants1 site · ChinaCompletes Sep 2027

Compare CT.gov Full analysis →

Recruiting

The Pediatric Lupus Nephritis Mycophenolate Mofetil (PLUMM) Study

Phase 2Lupus Nephritis

Mycophenolate MofetilMycophenolate Mofetil

Children's Hospital Medical Center, Cincinnati105 participants19 sites · United StatesCompletes Jan 2027

Compare CT.gov Full analysis →

Recruiting

Phase 1b/2 Study of IV Sarilumab in Adult With RA

Phase 1Phase 2Rheumatoid Arthritis

Sarilumab, SAR153191 SCSarilumab, SAR153191 IV

Sanofi140 participants12 sites · United StatesCompletes Oct 2028

Compare CT.gov Full analysis →

Recruiting

Efficacy and Safety of CAR-T Cells Therapy for Chronic or Refractory Primary Immune Thrombocytopenia (ITP)

Phase 1Phase 2ITP - Immune Thrombocytopenia

CAR-T cells

920th Hospital of Joint Logistics Support Force of People's Liberation Army of China10 participants1 site · ChinaCompletes Jan 2026

Compare CT.gov Full analysis →

Recruiting

Anti-CD19 CAR T-Cell Therapy in Refractory Systemic Autoimmune Diseases

Phase 1Phase 2Lupus Erythematosus, SystemicSystem; SclerosisANCA Associated Vasculitis

CAR T cell

Fondazione Policlinico Universitario Agostino Gemelli IRCCS8 participants1 site · ItalyCompletes Dec 2025

Compare CT.gov Full analysis →

Recruiting

Abatacept for the Treatment of Common Variable Immunodeficiency With Interstitial Lung Disease

Phase 2Interstitial Lung DiseaseCommon Variable Immunodeficiency

AbataceptPlacebo

Children's Hospital Medical Center, Cincinnati38 participants6 sites · United StatesCompletes Jul 2028

Compare CT.gov Full analysis →

Recruiting

VIBRANT: VIB4920 for Active Lupus Nephritis

Phase 2Lupus Nephritis

VIB4920Placebo for VIB4920

National Institute of Allergy and Infectious Diseases (NIAID)74 participants17 sites · United StatesCompletes Jun 2028

Compare CT.gov Full analysis →

Recruiting

Ublituximab in Autoantibody Positive Immune Mediated Necrotizing Myopathy

Phase 2Autoimmune Disorders

UblituximabPlacebo for Ublituximab

National Institute of Allergy and Infectious Diseases (NIAID)30 participants8 sites · United StatesCompletes Aug 2028

Compare CT.gov Full analysis →

Recruiting

A Clinical Trial to Investigate 18F-AzaFol in the Diagnosis of Large Vessel Vasculitis

Phase 2Giant Cell Arteritis

AzaFolFDG

Insel Gruppe AG, University Hospital Bern70 participants1 site · SwitzerlandCompletes May 2029

Compare CT.gov Full analysis →

Recruiting

A Clinical Study of CD19 Universal CAR-γδT Cells in Active Systemic Lupus Erythematosus

Phase 1Phase 2Systemic Lupus Erythematosus

CD19 Universal CAR-γδ T Cells

Union Hospital, Tongji Medical College, Huazhong University of Science and Technology15 participants1 site · ChinaCompletes Dec 2025

Compare CT.gov Full analysis →

Recruiting

A Study of Enpatoran in Participants With Cutaneous Manifestations of Lupus With or Without Systemic Disease

Phase 3Systemic Lupus Erythematosus (SLE)Cutaneous Lupus Erythematosus (CLE)

EnpatoranPlaceboStandard of care (SoC)

EMD Serono Research & Development Institute, Inc.202 participants60 sites · United States, Australia, BrazilCompletes May 2029

Compare CT.gov Full analysis →

Recruiting

A Single-arm, Dose-escalation Trial of Long-acting Recombinant Human IL-7 (NT-I7, Efineptakin Alfa) for Idiopathic CD4 Lymphopenia

Phase 1Phase 2Idiopathic CD4 Lymphopenia

Recombinant human interleukin (IL) 7-hyFc

National Institute of Allergy and Infectious Diseases (NIAID)60 participants1 site · United StatesCompletes Nov 2026

Compare CT.gov Full analysis →

Recruiting

An Artificial Intelligence-powered Approach to Precision Immunotherapy of Human Arthritis

Phase 2Rheumatoid Arthritis (RA)Rheumatology

dnaJP1Placebo

Prof Salvatore Albani124 participants1 site · SingaporeCompletes Nov 2028

Compare CT.gov Full analysis →

1–15 of 41

Explore/autoimmune immunology

Status

Phase

Pre-filtered to show active, later-stage trials with the strongest clinical signal.

41 results for “autoimmune immunology” · Recruiting · Phase 3 · Phase 2

Page 1 of 3

Recruiting

A Study of Nipocalimab in Adults With Moderate to Severe Systemic Lupus Erythematosus

Phase 3Lupus Erythematosus, Systemic

NipocalimabPlaceboStandard of care treatment

Janssen Research & Development, LLC600 participants260 sites · United States, Argentina, AustraliaCompletes Dec 2028

Compare CT.gov Full analysis →

Recruiting

Belimumab in Autoimmune Hepatitis

Phase 2Autoimmune Hepatitis

Belimumab Auto-Injector [Benlysta]

University Health Network, Toronto48 participants5 sites · CanadaCompletes Apr 2028

Compare CT.gov Full analysis →

Recruiting

Exploratory Study of Anti-BCMA-CD19 CAR-T Cell Therapy in Relapsed or Refractory IgG4-Related Disease

Phase 2IgG4 Related DiseaseB-cell Mediated Autoimmune Disorders

Anti-BCMA-CD19 CAR-T cells

Chinese PLA General Hospital9 participants1 site · ChinaCompletes Sep 2027

Compare CT.gov Full analysis →

Recruiting

The Pediatric Lupus Nephritis Mycophenolate Mofetil (PLUMM) Study

Phase 2Lupus Nephritis

Mycophenolate MofetilMycophenolate Mofetil

Children's Hospital Medical Center, Cincinnati105 participants19 sites · United StatesCompletes Jan 2027

Compare CT.gov Full analysis →

Recruiting

Phase 1b/2 Study of IV Sarilumab in Adult With RA

Phase 1Phase 2Rheumatoid Arthritis

Sarilumab, SAR153191 SCSarilumab, SAR153191 IV

Sanofi140 participants12 sites · United StatesCompletes Oct 2028

Compare CT.gov Full analysis →

Recruiting

Efficacy and Safety of CAR-T Cells Therapy for Chronic or Refractory Primary Immune Thrombocytopenia (ITP)

Phase 1Phase 2ITP - Immune Thrombocytopenia

CAR-T cells

920th Hospital of Joint Logistics Support Force of People's Liberation Army of China10 participants1 site · ChinaCompletes Jan 2026

Compare CT.gov Full analysis →

Recruiting

Anti-CD19 CAR T-Cell Therapy in Refractory Systemic Autoimmune Diseases

Phase 1Phase 2Lupus Erythematosus, SystemicSystem; SclerosisANCA Associated Vasculitis

CAR T cell

Fondazione Policlinico Universitario Agostino Gemelli IRCCS8 participants1 site · ItalyCompletes Dec 2025

Compare CT.gov Full analysis →

Recruiting

Abatacept for the Treatment of Common Variable Immunodeficiency With Interstitial Lung Disease

Phase 2Interstitial Lung DiseaseCommon Variable Immunodeficiency

AbataceptPlacebo

Children's Hospital Medical Center, Cincinnati38 participants6 sites · United StatesCompletes Jul 2028

Compare CT.gov Full analysis →

Recruiting

VIBRANT: VIB4920 for Active Lupus Nephritis

Phase 2Lupus Nephritis

VIB4920Placebo for VIB4920

National Institute of Allergy and Infectious Diseases (NIAID)74 participants17 sites · United StatesCompletes Jun 2028

Compare CT.gov Full analysis →

Recruiting

Ublituximab in Autoantibody Positive Immune Mediated Necrotizing Myopathy

Phase 2Autoimmune Disorders

UblituximabPlacebo for Ublituximab

National Institute of Allergy and Infectious Diseases (NIAID)30 participants8 sites · United StatesCompletes Aug 2028

Compare CT.gov Full analysis →

Recruiting

A Clinical Trial to Investigate 18F-AzaFol in the Diagnosis of Large Vessel Vasculitis

Phase 2Giant Cell Arteritis

AzaFolFDG

Insel Gruppe AG, University Hospital Bern70 participants1 site · SwitzerlandCompletes May 2029

Compare CT.gov Full analysis →

Recruiting

A Clinical Study of CD19 Universal CAR-γδT Cells in Active Systemic Lupus Erythematosus

Phase 1Phase 2Systemic Lupus Erythematosus

CD19 Universal CAR-γδ T Cells

Union Hospital, Tongji Medical College, Huazhong University of Science and Technology15 participants1 site · ChinaCompletes Dec 2025

Compare CT.gov Full analysis →

Recruiting

A Study of Enpatoran in Participants With Cutaneous Manifestations of Lupus With or Without Systemic Disease

Phase 3Systemic Lupus Erythematosus (SLE)Cutaneous Lupus Erythematosus (CLE)

EnpatoranPlaceboStandard of care (SoC)

EMD Serono Research & Development Institute, Inc.202 participants60 sites · United States, Australia, BrazilCompletes May 2029

Compare CT.gov Full analysis →

Recruiting

A Single-arm, Dose-escalation Trial of Long-acting Recombinant Human IL-7 (NT-I7, Efineptakin Alfa) for Idiopathic CD4 Lymphopenia

Phase 1Phase 2Idiopathic CD4 Lymphopenia

Recombinant human interleukin (IL) 7-hyFc

National Institute of Allergy and Infectious Diseases (NIAID)60 participants1 site · United StatesCompletes Nov 2026

Compare CT.gov Full analysis →

Recruiting

An Artificial Intelligence-powered Approach to Precision Immunotherapy of Human Arthritis

Phase 2Rheumatoid Arthritis (RA)Rheumatology

dnaJP1Placebo

Prof Salvatore Albani124 participants1 site · SingaporeCompletes Nov 2028

Compare CT.gov Full analysis →

1–15 of 41